Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib for Non-muscle Invasive Bladder Cancer
NCT02343614Phase 2Completed
- Sponsor
- Policlinico di Bari
- Start
- Mar 2003
- Primary completion
- Oct 2013
- Modality
- Orthosteric Ligands
01
Overview
Phase 2, open-label, single-arm trial of celecoxib in non-muscle-invasive bladder cancer (NMIBC), sponsored by Policlinico di Bari. Primary endpoints: Time to first recurrence at 5 years and Adverse Events at 5 years. Started Mar 2003; status: completed.
02
Drugs
celecoxib
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT02343614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02343614.